A new publication involving lixisenatide appeared on October 26, 2026. The study, titled "Glucagon-Like Peptide-1 Receptor Agonists and Risk of Arrhythmias: A Network Meta-Analysis," was published in the journal Heart Rhythm.
The publication is a network meta-analysis examining GLP-1 receptor agonists, a drug class that includes lixisenatide, in relation to arrhythmia risk. No specific findings, results, or conclusions from the analysis have been reported here.
Lixisenatide remains an approved compound. This entry reflects only the existence and bibliographic details of the publication as listed in the source record, including its title, journal, and publication date.
Readers interested in additional background on lixisenatide can consult the compound overview for further context.